MICB and plasma cell myeloma: In addition to the increase in CD38 levels, we have demonstrated that tinostamustine augments the expression of several NKG2D ligands, especially MICA and MICB, in myeloma cell lines, an event that may also be beneficial when combining tinostamustine with immunotherapy treatments.